AQR Capital Management
PLX icon

AQR Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

AQR Capital Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$66.2K Buy
+30,493
New +$75.7K ﹤0.01% 3702
2024
Q3 		– Sell
-57,106
Closed -$66.8K – 2855
2024
Q2 		$66.8K Buy
+57,106
New +$67.5K ﹤0.01% 2526

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

AQR Capital Management's PLX Position: Q1 2026 in Review

AQR Capital Management opened a new position in Protalix BioTherapeutics (PLX) in Q1 2026: 30,493 shares worth $66.2K. The stake represents ﹤0.01% of the portfolio and ranks #3702 among its holdings. This is a return to the name: AQR Capital Management previously reported a position in PLX as recently as Q2 2024.

AQR Capital Management first reported a position in PLX in Q2 2024 and has held it in 2 quarters since. The position peaked at $66.8K in Q2 2024. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • AQR Capital Management held 30,493 shares of Protalix BioTherapeutics worth $66.2K as of Q1 2026.
  • Protalix BioTherapeutics was a new AQR Capital Management position in Q1 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3702 holding.
  • AQR Capital Management first reported a position in Protalix BioTherapeutics in Q2 2024 and has held it in 2 quarters since.
  • AQR Capital Management's Protalix BioTherapeutics position peaked at $66.8K in Q2 2024.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.